Dramatic study results point to the potential for a steroid-sparing option for patients with the underrecognized multiorgan ...

Despite the very positive setup facing Amgen as a result of its ongoing and future investments in developing new ...

The excitement around the new weight-loss industry is overtaking other disease areas and portfolios for publicly traded ...

Biotech companies are racing to find Ozempic 2.0, hoping for a slice of a multi-billion-dollar industry. A few stand-out ...

CHICAGO -- A long-acting GIP/GLP-1 receptor agonist conferred significant clinical benefit for people with obesity and ...

Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a day after ...

Analyzing Amgen's stock drop, management's response, and potential for growth in GLP-1 candidate MariTide in a volatile market. Click here to read more.

We recently compiled a list of the 10 Best Immunotherapy Stocks to Buy Now. In this article, we are going to take a look at ...

Analysts cited data from a phase one study showing the highest dose of Amgen’s MariTide was linked to roughly 4% loss of bone ...

WASHINGTON -- Patients with IgG4-related disease appeared to benefit from inebilizumab (Uplizna), currently approved for ...

Amgen (AMGN) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some of the key factors that could influence the stock's performance in the near ...

(Reuters) -Amgen said on Wednesday there was no link between its experimental weight-loss drug and changes in bone density, a ...